Lv1
28 积分 2025-12-20 加入
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases
4小时前
待确认
Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis
16天前
已完结
Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
16天前
已完结
Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials
1个月前
已完结
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
1个月前
已完结
A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease
2个月前
已完结
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
2个月前
已完结
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
2个月前
已完结
A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease
3个月前
已完结
SYHX1901, an oral dual Janus kinase and spleen tyrosine kinase inhibitor, for moderate-to-severe plaque psoriasis: A randomized phase 2 trial
3个月前
已完结
皖公网安备34019202002308
